CSL Osake

CSL Ostovelat

Delisted·19.6.2026

Ostovelat yhtiöstä CSL (CSL.AX) 8.8.2026 päivämäärällä on 808,00 M USD. Edellisenä vuonna Ostovelat oli 867,00 M USD — muutos −6,81 % (matalampi).

Ostovelat

808,00 MUSD

YoY

−6,81%

Viimeksi päivitetty:

Ostovelat yhtiöstä CSL on 2026 808,00 M USD. Ostovelat yhtiöstä CSL oli 2025 867,00 M USD. Se laskee −6,81% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

CSL Osakeanalyysi

Mitä CSL tekee? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset CSL osakkeesta

Yhtiön CSL Ostovelat on 808,00 M USD vuonna 2026.

Ostovelat yhtiöstä CSL muuttui arvosta 867,00 M USD arvoon 808,00 M USD, mikä edustaa −6,81 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää Ostovelat CSL:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Ostovelat edustavat rahaa, jonka yritys on velvoitettava maksamaan toimittajille vastaanotetuista tavaroista ja palveluista. Ne ovat käyttöpääomahallinnan keskeinen komponentti.

Ostovelat:n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata Ostovelat:n CSL historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tase — CSL

Kaikki tunnusluvut — CSL